PCOS & Fertility: Can GLP-1s Help?

Key Takeaways

Multiple recent studies suggest GLP-1 receptor agonists may improve metabolic and hormonal markers in women with PCOS, including insulin resistance, androgen levels, and menstrual cycle regularity.
A 2025 network meta-analysis found GLP-1 receptor agonists were among the most effective options for reducing body weight and improving metabolic outcomes in women with PCOS compared with metformin and inositol.
Early real-world data show incretin-based therapies are being used more frequently in women with PCOS, though long-term evidence is still limited.
Current systematic reviews flag important safety gaps for GLP-1 medications during preconception, pregnancy, and breastfeeding, and most guidelines recommend stopping them before conception.
Because PCOS affects women differently, any treatment decision—including whether a GLP-1 medication is appropriate—should be made with a qualified healthcare provider.

Why does PCOS affect metabolism and hormones at the same time?

PCOS tangles metabolism and hormones together because insulin resistance — when the body’s cells stop responding well to insulin (the hormone that moves sugar from your blood into your cells) — drives both problems at once. Fix one, and you often nudge the other.

Here is how that loop works in practice:

Insulin resistance is the starting point. When cells ignore insulin’s signal, the pancreas pumps out more insulin to compensate. Those high insulin levels travel to the ovaries and tell them to make more androgens (male-type hormones like testosterone). Elevated androgens then disrupt ovulation and contribute to the irregular periods and cyst formation that define PCOS. This metabolic-hormonal interplay is why researchers now describe PCOS as a reproductive-metabolic condition — not purely a gynecological one.
Excess androgens circle back to worsen metabolism. Higher testosterone levels promote fat storage around the abdomen. Abdominal fat is metabolically active in a way that deepens insulin resistance further, tightening the loop. A systematic review and meta-analysis of randomized controlled trials confirms that women with PCOS carry a disproportionate burden of both insulin resistance and androgen excess compared with women without the condition.
The ovaries are not passive bystanders. GLP-1 receptors — the same molecular targets that GLP-1 medications activate — exist in ovarian tissue. When those receptors are stimulated, they appear to directly reduce androgen production at the ovarian level, separate from any weight loss effect. A scientific literature review on incretin therapy and ovarian function describes this direct pathway.
Chronic low-grade inflammation adds a third layer. PCOS is associated with ongoing, low-level inflammation throughout the body. That inflammation worsens insulin resistance independently of weight, which means the metabolic-hormonal cycle can persist even in women who are not significantly overweight. The reproductive-metabolic framework paper identifies inflammation as a key driver sustaining this cycle.

Because insulin resistance, androgen excess, and inflammation feed each other in a continuous loop, treatments that address metabolism — including GLP-1 medications — can produce hormonal changes as a downstream effect. That is not a coincidence or a bonus. It reflects how tightly the two systems are wired together in PCOS.

This content is for general informational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Talk with a qualified healthcare provider about your individual situation before making any changes to your care.

What does the research say about GLP-1s and PCOS symptoms?

Early research suggests GLP-1 medications can improve several key PCOS symptoms — including weight, insulin resistance, and hormone levels — though the evidence is still growing and results vary from person to person.

PCOS (polycystic ovary syndrome) is a hormonal condition affecting how the ovaries work, closely tied to insulin metabolism. GLP-1 medications were designed for blood sugar and weight management, but because PCOS and metabolic health intertwine so deeply, researchers have begun studying whether these drugs might address PCOS-specific concerns.

What the studies are finding:

Weight and waist size: A systematic review and meta-analysis of randomized controlled trials found that GLP-1 receptor agonists significantly reduced body weight and BMI in women with PCOS compared to control groups. Smaller waist measurements followed weight loss in several trials.
Insulin resistance: Insulin resistance — when the body’s cells stop responding well to insulin, causing blood sugar to rise — improved with GLP-1 use across multiple studies. A network meta-analysis comparing GLP-1s, metformin, and inositol found GLP-1s performed competitively on metabolic markers, including fasting insulin levels.
Androgen levels: Androgens are hormones like testosterone that, when elevated, drive symptoms like excess hair growth and acne. A scientific literature review found incretin-based therapies (the drug class GLP-1s belong to) showed promise in lowering androgen levels, which could ease those visible symptoms.
Menstrual regularity: Cycle regularity improved in some trials. A prospective randomized controlled trial of tirzepatide combined with metformin in women with PCOS reported improvements in menstrual frequency over a short treatment period.
Ovarian function: Researchers are actively exploring whether GLP-1 receptors exist directly on ovarian tissue, which would mean these medications could act on the ovaries themselves — not just through weight loss. A reproductive-metabolic framework review outlines this emerging area of investigation.

Real-world data adds texture to the clinical picture. A Polish cohort study tracking actual prescribing patterns found GLP-1 use in women with PCOS rising sharply, with clinicians increasingly reaching for these medications in practice. An evidence map of incretin-based medications in PCOS describes the research as promising but still maturing — more large, long-term trials are needed before firm conclusions can be drawn.

This content is for general informational purposes only and is not medical advice. It does not replace consultation with a qualified healthcare professional. Never start, stop, or change a medication based on information you read here.

How do GLP-1s compare with metformin and inositol for PCOS?

GLP-1 medications, metformin, and inositol all target insulin resistance — a core driver of PCOS — but they work through different mechanisms and produce meaningfully different results. A recent network meta-analysis found that GLP-1 receptor agonists outperformed both metformin and inositol on several key metabolic and weight-related measures in women with PCOS.

What each option actually does

Metformin is an oral diabetes drug that lowers the amount of glucose your liver releases and makes your cells more sensitive to insulin. Doctors have prescribed it for PCOS for decades because it is inexpensive and well-studied.
Inositol (specifically myo-inositol and D-chiro-inositol) is a naturally occurring compound, often sold as a supplement, that appears to improve how cells respond to insulin signals. Evidence for it is growing but remains thinner than for the other two options.
GLP-1 receptor agonists (like semaglutide or liraglutide) are injectable or oral medications that mimic a gut hormone your body already makes. They slow digestion, reduce appetite, and improve insulin sensitivity all at once.

How the evidence stacks up

A network meta-analysis that directly compared all three approaches found GLP-1 receptor agonists produced greater reductions in body weight, BMI, waist circumference, fasting insulin, and testosterone levels than either metformin or inositol in women with PCOS. This matters because high testosterone and excess weight rank among the most disruptive features of the condition.

A separate systematic review and meta-analysis of randomized controlled trials confirmed that GLP-1 receptor agonists significantly reduced body weight, fasting blood sugar, and insulin resistance markers in PCOS patients compared with control groups.

Combination approaches are being studied

Some researchers are exploring whether pairing a GLP-1 medication with metformin delivers better results than either drug alone. A randomized controlled trial in overweight and obese Chinese women with PCOS found that combining tirzepatide (a dual GLP-1/GIP receptor agonist) with metformin produced short-term improvements in metabolic and hormonal markers. Research here remains early.

The practical takeaway

No single option is right for everyone. GLP-1 medications appear to offer broader metabolic benefits, but they cost significantly more than metformin and are not yet available everywhere. Inositol is accessible over the counter but carries less clinical evidence behind it. Your doctor can weigh your specific lab results, symptoms, insurance coverage, and reproductive goals to help you decide what fits your situation.

This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or supplement.

Can GLP-1 medications affect ovulation and menstrual cycles?

Yes, GLP-1 medications can influence ovulation and menstrual cycles, particularly in people with hormonal conditions like PCOS (polycystic ovary syndrome — a condition where the ovaries produce excess androgens, often disrupting periods and ovulation). The effect appears tied largely to weight loss and improvements in insulin signaling, rather than direct action on the reproductive system alone.

Cycles can change. Here’s what the research shows, and what it means for you.

The weight-insulin connection

Excess body weight raises insulin levels, and high insulin tells the ovaries to produce more androgens (male-type hormones). That hormonal imbalance suppresses or delays ovulation. When GLP-1 medications reduce body weight and lower insulin resistance, that chain of events reverses — sometimes enough to restore more regular cycles.

A 2025 systematic review and meta-analysis found that GLP-1 receptor agonists significantly improved menstrual regularity in women with PCOS compared to control groups. A separate network meta-analysis comparing GLP-1 medications, metformin, and inositol in women with PCOS showed that GLP-1 drugs produced meaningful improvements in metabolic markers closely tied to cycle regularity.

What this looks like in practice

More regular periods. A real-world cohort study of women with PCOS using incretin-based therapies (the drug class GLP-1 medications belong to) reported improvements in menstrual regularity over time.
Possible return of ovulation. A prospective randomized controlled trial of tirzepatide (a dual GLP-1/GIP receptor agonist) combined with metformin in women with PCOS showed improvements in ovarian function markers after short-term treatment.
Hormonal shifts. A scientific literature review found that incretin-based therapies reduce androgen levels and improve ovarian function — two factors directly tied to cycle regularity.

This matters for pregnancy planning

Restored ovulation means restored fertility — even if your periods were irregular before. A reproductive-metabolic framework review highlights that clinicians increasingly recognize GLP-1 medications as having meaningful reproductive implications, not just metabolic ones. If you are not trying to conceive, talk to your provider about contraception. If you are trying to conceive, current guidance recommends stopping GLP-1 medications before pregnancy, as safety data during pregnancy remains limited — a point underscored by a systematic review of GLP-1 safety in preconception and pregnancy (source).

Cycles vary. Not everyone notices a change. Your response depends on your starting weight, hormone levels, and overall health — which is exactly why this conversation belongs with your doctor or a reproductive endocrinologist.

This content is for general informational purposes only and is not medical advice. It does not replace the guidance of a qualified healthcare professional. Always consult your doctor or another licensed provider before making any decisions about your medications, fertility, or reproductive health.

What do women need to know about GLP-1 safety before and during pregnancy?

Stop GLP-1 medications before you become pregnant. Current evidence and clinical guidance recommend discontinuing GLP-1 receptor agonists (GLP-1 RAs — a class of weight-loss and diabetes drugs that mimic a gut hormone to reduce appetite) before conception, because safety data during human pregnancy remain limited.

Here is what the research shows right now:

Animal studies raise concern. Studies in animals have found links between GLP-1 RA exposure and fetal harm, including growth problems and structural abnormalities. Human data remain too sparse to rule out similar risks, according to a 2025 systematic review that examined maternal, fetal, and newborn outcomes across available studies.
Accidental exposure does happen. GLP-1 medications can improve ovulation in women with conditions like PCOS (polycystic ovary syndrome — a hormonal condition that affects fertility), meaning some women become pregnant unexpectedly while still taking the drug. A reproductive-metabolic framework review highlights this as a real clinical concern that deserves proactive planning.
The timing window matters. Semaglutide (brand names Ozempic, Wegovy) stays in the body for weeks after the last dose. The systematic review on pregnancy safety notes that stopping at least two months before a planned pregnancy is a commonly discussed precaution — though your own provider should set your specific timeline.
Breastfeeding data are also thin. The same systematic review found almost no high-quality human evidence on GLP-1 use during lactation, so most guidance recommends avoiding these medications while breastfeeding.
Fertility itself may change on GLP-1s. Research shows GLP-1 RAs can improve menstrual regularity and ovulation, particularly in women with PCOS, as documented in a literature review on ovarian function and a network meta-analysis. Better fertility is a benefit — and a reason to use reliable contraception if pregnancy is not the goal.

The practical takeaway: Tell your prescriber if you are trying to conceive, think you might be pregnant, or are breastfeeding. Do not stop or adjust your medication on your own. A healthcare provider can help you weigh the risks, plan a safe stopping point, and discuss alternative options for managing weight during pregnancy.

What questions should you bring to your doctor about GLP-1s and PCOS?

Bringing a focused list of questions to your appointment helps you and your doctor decide together whether a GLP-1 medication makes sense for your specific PCOS picture. The questions below are grounded in what current research actually shows — and, just as importantly, where the evidence still has gaps.

Questions about your personal health profile

“Do I have insulin resistance, and if so, how does that change which medication you’d recommend?” Insulin resistance is extremely common in PCOS. A network meta-analysis found GLP-1 receptor agonists improved metabolic markers in women with PCOS, but your individual lab values shape whether a GLP-1, metformin, or a combination fits best.
“Should we check my testosterone and LH levels before I start, so we have a baseline?” A systematic review and meta-analysis found GLP-1 medications reduced testosterone levels in women with PCOS — having a starting number lets you track real change.
“Are any of my current medications likely to interact with a GLP-1?”

Questions about what the medication may — and may not — do for PCOS symptoms

“Could this help my cycle become more regular?” A literature review on incretin therapy and ovarian function (source) reports improvements in menstrual regularity in some women, but results vary. Ask your doctor what realistic expectations look like for you.
“Will it reduce my androgen symptoms, like excess hair growth or acne?” The testosterone reductions seen in clinical trials are promising. They are not guaranteed for every person.
“Is there evidence this could support my fertility?” Research framing GLP-1s within a reproductive-metabolic framework suggests these medications may influence reproductive hormones, but your doctor needs to evaluate your full fertility picture before drawing conclusions.

Questions about safety — especially if pregnancy is possible

This matters. A lot. A systematic review of GLP-1 and dual GLP-1/GIP medications during preconception, pregnancy, and breastfeeding (source) found limited safety data for use during pregnancy itself.

“If I become pregnant while taking this, what should I do immediately?”
“How long before trying to conceive should I stop the medication?”
“What contraception do you recommend while I’m on a GLP-1?”

Questions about monitoring and follow-up

“How often will we check my labs while I’m on this?” A real-world cohort study found that women with PCOS using incretin-based therapies had varied clinical profiles — routine monitoring helps catch what a one-time snapshot misses.
“What results would tell you this medication is working for me specifically?”
“At what point would you recommend we try a different approach?”

Not medical advice. This content is for general informational purposes only. It does not replace the guidance of a licensed healthcare professional. Always consult your doctor, endocrinologist, or OB-GYN before starting, stopping, or changing any medication.

FAQ

Are GLP-1 medications approved specifically for PCOS?

As of the time of publication, GLP-1 receptor agonists are not specifically FDA-approved for PCOS. They are approved for type 2 diabetes and, in some cases, obesity. Research into their use for PCOS is ongoing, and any off-label use should be discussed with a healthcare provider.

Can GLP-1 medications help restore regular periods in women with PCOS?

Several studies reviewed here report improvements in menstrual regularity among women with PCOS who used incretin-based therapies, likely linked to reductions in insulin resistance and androgen levels. However, results vary, and this is not a guaranteed outcome for every individual.

Is it safe to take a GLP-1 medication if I am trying to conceive?

Current systematic review evidence highlights significant gaps in safety data for GLP-1 medications during preconception and pregnancy. Most clinical guidance recommends discontinuing these medications before attempting conception. Always consult your doctor before making any changes if you are planning a pregnancy.

How do GLP-1 receptor agonists work differently from metformin for PCOS?

Metformin primarily reduces liver glucose production and improves insulin sensitivity. GLP-1 receptor agonists work by mimicking the GLP-1 hormone to stimulate insulin release, suppress glucagon, slow gastric emptying, and reduce appetite. Research suggests they may produce greater weight loss than metformin, which can itself improve PCOS symptoms.

What is tirzepatide, and is it different from a standard GLP-1 medication?

Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates two hormone pathways instead of one. A 2025 randomized controlled trial in Chinese women with PCOS found short-term combined treatment with tirzepatide and metformin improved metabolic and hormonal outcomes, though longer-term data are still needed.

Should I stop a GLP-1 medication if I become pregnant unexpectedly?

If you become pregnant while taking a GLP-1 medication, contact your healthcare provider immediately. Current safety reviews indicate insufficient data to confirm these medications are safe during pregnancy, and your provider will guide you on next steps.

This article is for general information and is not medical advice. GLP-1 medications are prescription drugs that require clinical supervision — talk to a licensed healthcare provider before starting, stopping, or changing any treatment.